Pilot Study of Rituximab and Brentuximab Vedotin With Deferred BMT for Relapsed Classical Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Rituximab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 16 Oct 2018 Status changed from active, no longer recruiting to discontinued due to low accrual
- 31 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 17 May 2016 Brentuximab vedotin will be given for up to 10 doses (cycles) instead of 8 doses (cycles).